Acute Myelogenous Leukemia in Adolescents and Young Adults: What Is the Optimal Therapy?
Category: Pediatric Cancer Meeting: 2006 Educational Book Author(s): Robert J. Arceci, MD, PhD, Alan Burnett, MD, FRCP, Elihu Estey, MD, Robert Hills, DPhil, and William G. Woods, MD Manuscript Summary: Overview: Over the past several years there has been increasing interest and debate on the optimal treatment for adolescents and young adults with a variety of cancers. This interest and debate has occurred in part because of reports showing outcomes based on this important transitional age group. In addition, there has been a growing recognition that this group of patients – particularly adolescents – are underserved in terms of accrual to clinical trials and comprehensive centers. Adolescents and young adults with acute myelogenous leukemia have been treated both by pediatric and medical oncologists, but often not on the same protocol. One exception is the Medical Research Council trials. In order to determine the optimal therapy for adolescents and young adults with acute myelogenous
